

Assistant Commissioner for Patents

Serial No.: 09/811,346

Please amend the specification (Pages 1-19) as set forth in the marked-up version thereof, attached hereto. A clean copy of the specification to serve as a substitute specification (numbered pages 1-16). is also included herewith.

IN THE CLAIMS:

Please rewrite claims 4-6 and 9 as follows:

4. (Amended) The method of Claim 3 wherein lipid carrier particles comprise all-trans retinoic acid, lipid, and a triglyceride: wherein a molar ratio of retinoid to lipid is at least about 15:85; the triglyceride is at least about 15% by weight of the composition; and [where] the composition is stable in an aqueous environment.

5. (Amended) The method of Claim 1 comprising administering said retinoid composition in at least one dose over a period of at least one-half hour.

6. (Amended) The method of Claim 1 wherein said retinoid composition is administered at a frequency no greater than about every other day.

9. (Amended) A method of inhibiting the growth of cancer cells comprising co-timely exposing cancerous cells to: a) a therapeutically effective amount of a composition which comprises at least one interferon and b) a therapeutically effective amount of a retinoid, wherein said retinoid is associated with lipid carrier particles.

Assistant Commissioner for Patents

Serial No.: 09/811,346

Please add the following new claims:

Pub 1126

¹⁰
11. (New) The method of Claim 1 wherein the cancer is selected from the group consisting of renal cancer, breast cancer, head cancer, and neck cancer.

11.

12. (New) The method of Claim 9 wherein the cancer is selected from the group consisting of renal cancer, breast cancer, head cancer, and neck cancer.

12

13. (New) The method of Claim 1 wherein the cancerous cells are exposed in vivo.

13

14. (New) The method of Claim 9 wherein the cancerous cells are exposed in vivo.

14

15. (New) The method of Claim 1, wherein the interferon is selected from the group consisting of alpha, beta, and gamma interferon.

15

16. (New) The method of Claim 15, wherein the interferon is alpha interferon.

16

17. (New) The method of claim 16, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

17

18. (New) The method of claim 3, wherein the amount of all-trans retinoic acid is about 15-300 mg/m².

Assistant Commissioner for Patents

Serial No.: 09/811,346

~~18.~~

19. (New) The method of claim 18, wherein the amount of all-trans retinoic acid is about 15 mg/m².

~~20.~~

20. (New) The method of Claim 9, wherein the interferon is selected from the group consisting of alpha, beta, and gamma interferon.

~~21.~~

21. (New) The method of Claim 20, wherein the interferon is alpha interferon.

~~22.~~

22. (New) The method of claim 21, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

~~23.~~

23. (New) A method of inhibiting the growth of cancer cells, wherein the cancer cells are selected from the group consisting of renal, head, neck, and breast cancer cells, comprising exposing said cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein the retinoid is all-trans retinoic acid and is associated with lipid carrier particles.

~~24.~~

24. (New) The method of claim 23 wherein the interferon is selected from the group consisting of alpha, beta, and gamma interferon.

~~25.~~

25. (New) The method of claim 24 wherein the interferon is alpha interferon.

Assistant Commissioner for Patents

Serial No.: 09/811,346

~~25~~

~~26.~~ (New) The method of claim 25, wherein alpha interferon is administered in an amount of about 1 to about 25 million IU.

~~26~~

~~27.~~ (New) The method of claim 23, wherein the amount of all-trans retinoic acid is about 15-300 mg/m².

~~27~~

~~28.~~ (New) The method of claim 27, wherein the amount of all-trans retinoic acid is about 15 mg/m².

~~28~~

~~29.~~ (New) A method of inhibiting the growth of cancer cells, wherein the cancer cells are selected from the group consisting of renal, head, neck, and breast cancer cells, comprising exposing said cancerous cells to a therapeutically effective amount of a composition which comprises at least one interferon and a retinoid, wherein the retinoid is all-trans retinoic acid and is associated with lipid carrier particles and the at least one interferon is alpha interferon.

~~29~~

~~30.~~ (New) The method of Claim 4 wherein the cancer is a renal cell cancer.

~~30~~

~~31.~~ (New) The method of Claim 11 wherein the cancer is a renal cell cancer.

~~31~~

~~32.~~ (New) The method of Claim 12 wherein the cancer is a renal cell cancer.
